Activating and inhibitory signaling in mast cells: New opportunities for therapeutic intervention? Vanessa L. Ott, PhD, John C. Cambier, PhD Journal of Allergy and Clinical Immunology Volume 106, Issue 3, Pages 429-440 (September 2000) DOI: 10.1067/mai.2000.109428 Copyright © 2000 Mosby, Inc. Terms and Conditions
Fig. 1 Inhibition of FcϵRI signaling pathways by FcγRIIB. DAG, Diacylglycerol; PKC, protein kinase C; IP3, Ins (3,4,5) P3. Journal of Allergy and Clinical Immunology 2000 106, 429-440DOI: (10.1067/mai.2000.109428) Copyright © 2000 Mosby, Inc. Terms and Conditions
Fig. 2 ITIM-containing inhibitory receptors expressed in mast cells. SHPS-1, src homology 2 domain–containing phosphatase substrate 1; BIT , brain Ig-like molecules with tyrosine-based activation motifs; KLRG1, killer cell lectin-like receptor G1. Journal of Allergy and Clinical Immunology 2000 106, 429-440DOI: (10.1067/mai.2000.109428) Copyright © 2000 Mosby, Inc. Terms and Conditions